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Background. Tuberculin-specific T-cell responses have low diagnostic specificity in BCG vaccinated populations. While
subunit-antigen (e.g. ESAT-6, CFP-10) based tests are useful for diagnosing latent tuberculosis infection, there is no reliable
immunological test for active pulmonary tuberculosis. Notably, all existing immunological tuberculosis-tests are based on T-
cell response size, whereas the diagnostic potential of T-cell response quality has never been explored. This includes surface
marker expression and functionality of mycobacterial antigen specific T-cells. Methodology/Principal Findings. Flow-
cytometry was used to examine over-night antigen-stimulated T-cells from tuberculosis patients and controls. Tuberculin and/
or the relatively M. tuberculosis specific ESAT-6 protein were used as stimulants. A set of classic surface markers of T-cell naı ¨ve/
memory differentiation was selected and IFN-c production was used to identify T-cells recognizing these antigens. The
percentage of tuberculin-specific T-helper-cells lacking the surface receptor CD27, a state associated with advanced
differentiation, varied considerably between individuals (from less than 5% to more than 95%). Healthy BCG vaccinated
individuals had significantly fewer CD27-negative tuberculin-reactive CD4 T-cells than patients with smear and/or culture
positive pulmonary tuberculosis, discriminating these groups with high sensitivity and specificity, whereas individuals with
latent tuberculosis infection exhibited levels in between. Conclusions/Significance. Smear and/or culture positive
pulmonary tuberculosis can be diagnosed by a rapid and reliable immunological test based on the distribution of CD27
expression on peripheral blood tuberculin specific T-cells. This test works very well even in a BCG vaccinated population. It is
simple and will be of great utility in situations where sputum specimens are difficult to obtain or sputum-smear is negative. It
will also help avoid unnecessary hospitalization and patient isolation.
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Tuberculosis. PLoS ONE 2(8): e735. doi:10.1371/journal.pone.0000735
INTRODUCTION
The goal of this work was to establish a new biomarker for clinical
tuberculosis based on measurable changes that TB specific CD4
T-cells undergo as they differentiate in response to virulent
mycobacteria. The diagnosis of acute tuberculosis is usually based on
characteristic X-ray findings, clinical symptoms, and positive
sputum-smear or culture. However, even if the sputum-smear is
negative, patients suspected to have active pulmonary TB will
frequently be hospitalized and treated until culture results are
obtained. This is an unnecessary burden on the patient and public
spending if cultures turn out negative. Unfortunately, T-cell
responses to tuberculin have no diagnostic value in BCG vaccinees
unless very strongly positive. Meanwhile, T-cell responses to the
relatively M. tuberculosis specific ESAT-6 protein are the gold
standard in the detection of latent tuberculosis infection (more
recently in connection with other culture filtrate proteins) [1–5],
but were reported not to be reliable for the diagnosis of acute TB
[6,7]. As a matter of fact, a rapid and reliable immunological test
for active pulmonary tuberculosis does not exist to date.
The role of T-cells in controlling TB is dramatically illustrated
by the HIV pandemic. Whereas only 10% of latently TB infected
but otherwise healthy individuals progress to active TB in their
lifetime, this figure increases to 10% per year in HIV infected
individuals [8]. This observation is strong evidence that CD4 T-
helper-cells, which are gradually lost in HIV infection, have
a central role in controlling TB. Upon activation they can release
IFN-c, which drives monocytes to destroy intracellular mycobacteria.
The subsequent production of TNF-a by monocytes is essential for
containing mycobacteria inside granulomas [9]. Various other
immune cells including CD8 T-cells appear to contribute to the
control of TB [10].
Since CD4 T-cells are so important in the defence against TB,
we were hoping to find differences in the degree of differentiation
resulting from the ‘one-off’ stimulus provided by BCG vaccination
on the one hand and the exposure to virulent replicating
mycobacteria on the other. Given such differences, this new type of
test would also be able to be used in a BCG-vaccinated population,
where tuberculin based tests are normally difficult to use. In this
and our previous studies [11], the T-cells that responded by
production of IFN-c, TNF-a, or IL-2 to short term (16h) ex-vivo
stimulation with tuberculin (purified protein derivate, or PPD) or
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in regards of cytokine production (with respect to each antigen)
and were almost exclusively CD4-positive. This was an additional
reason why we focused on this subset and IFN-c production.
Patterns of antigen-dependent T-cell differentiation have been
a central issue in T-cell immunology for a number of years both in
humans and animal models [12–15]. Changes in surface marker
expression reflect changes in T-cell function, circulation pathways,
and co-stimulation requirements, for example. Such changes can
be visualized very efficiently by flow-cytometry [16] and, as
a result, this method has been very commonly used to research
HIV-specific T-cells. However, it was not until recently that it was
first applied to TB [6,11,17,18].
CD27 is a receptor for co-stimulation expressed on the T-cell
surface and down-regulated when T-cells progress from a non-
antigen experienced towards a terminal memory stage. It was
recently shown that IFN-c producing CD4 T-cells in the lungs of
TB infected mice are predominantly CD27-negative [19]. IFN-c
being an important player in the immune response against TB [9],
these CD27-negative CD4 T-cells may be instrumental in
controlling infection. To build on this discovery, the distribution
of CD27 on IFN-c producing tuberculin-reactive CD4 T-cells in
TB infected humans was the central parameter in our study. This
work was done on blood cells rather than pulmonary lymphocytes;
however, we discovered that the measurement of CD27 expression
on tuberculin-reactive human CD4 T-cells is a useful and rapid
tool for the diagnosis of active pulmonary tuberculosis. Results can
be obtained in less than 24 hours.
METHODS
Patients and patient materials
Smear and/or culture positive pulmonary TB was established by positive
microscopy and/or culture of sputum and/or bronchio-alveolar
lavage (BAL) fluid. Smear and culture negative Pulmonary TB refers to
TB diagnosed in the absence of positive sputum microscopy or
culture, based on X-ray lesions, positive histology of biopsy
materials, and/or response to TB therapy. All individuals
recruited (TB patients, control patients, healthy donors) had been
BCG-vaccinated in early childhood unless specifically stated as for
some of the latently infected individuals (BCG vaccination being
obligatory in the former German Democratic Republic of which
almost all recruited patients used to be citizens). None of the tested
patients or controls were known or suspected to be HIV-
seropositive. HIV serostatus was routinely obtained in TB patients
but not the other donors. All patients were recruited at
Lungenklinik Lostau, Lostau, Germany between 1/2005 and
10/2006. Samples were transported within 4 hours of collection to
the Institute for Medical Immunology, Charite ´ – Universitaets-
medizin Berlin, Berlin, Germany.
Blood from more than 30 patients with TB at different stages of
treatment was used to establish antibody staining panels using
tuberculin and/or ESAT-6 for stimulation. An initial comparative
and retrospective study focused on the distribution of CD27 on
tuberculin-reactive CD4 T-cells and included 6 patients with open
pulmonary TB (4 female, 2 male, age 23–79 years) and 31 healthy
individuals with no signs or symptoms of TB but various degrees of
exposure (household contacts, health care workers in a lung
hospital, medical students, and unexposed healthy blood donors;
23 female, 8 male, age 22–69 years). Within this group 5
individuals had latent TB infection, 17 were highly exposed, and
9 were considered unexposed. The diagnosis of latent TB infection
was established by a positive response to tuberculin in non-BCG
vaccinated individuals (n=3). Two individuals who had shared
their bed with a patient with smear positive TB where also
classified as having latent TB. In individuals classified as ‘highly
exposed’ latent TB infection had not been conclusively demon-
strated but for some of them would be suggested by their very close
and continued exposure. These included hospital personnel with
regular direct contact with TB, including some regularly
performing BAL on TB patients.
A blinded prospective study was designed to confirm the results
of the initial study. The diagnoses relating to coded samples were
not revealed to the lab until results had been reported back in print
to the clinicians obtaining and coding the samples. For this study
31 additional patients with smear and/or culture positive or smear
and culture negative pulmonary TB (11 female, 20 male, median
age 51 years, range 15–96 years) were recruited within two
months of treatment initiation, 9 patients at follow-up at least
one year after beginning of therapy, and 20 control patients with
no known history of or exposure to TB (6 female, 14 male, age 40–
76 years). Disease severity in TB patients was based on the
number and size of lesions observed on X-ray, however, these data
were not used to subgroup patients. All TB patients except for one
had more than one lesion on X-ray with at least one lesion larger
than 3 cm diameter. Treatment was based on triple (isoniazid,
ethambutol, and rifampicin) or quadruple (triple plus pyrazina-
mide) regimen. It was continued for one year in all patients and
prolonged depending on follow-up evaluation. In most cases, TB
culture results were pending at the time of sample collection for
flow-cytometry whereas a sputum smear had been obtained. Blood
was drawn into citrated blood collection tubes following written
informed consent as approved by the Charite ´ Ethics Committee.
The study protocol was in accordance with the Declaration of
Helsinki. A flow diagram of the study is presented in Fig. 1.
Cell preparation and cytokine induction assay
This method was described in detail elsewhere [11]. Samples were
processed immediately, within 4 hours of blood collection. Briefly,
aliquots of 400 ml of PBMC suspended in complete culture media
(5610
6 cells/ml) were placed in 5 ml polypropylene tubes (BD,
Heidelberg, Germany). Stimulants were added in a volume of
100 ml( 1 mg/ml final concentration for each of 21 ESAT-6
peptides or 10 ml/ml final concentration of tuberculin (PPD, SSI,
Copenhagen, Denmark)). After 2 hours of incubation (standard
incubator) 2 ml Brefeldin A (5 mg/ml working solution in DMSO)
was added and the volume adjusted to 1 ml (culture media). After
16 hours ice-cold PBS (3 ml) was added and tubes were
centrifuged. Supernatants were removed, pellets were resuspended
(2mM EDTA in PBS) and incubated (37uC water bath, 10 min).
Adherent cells were detached by two subsequent wash/centrifu-
gation steps (0.5 % (w/v) BSA (Biochrom, Germany) and 0.1%
sodium-azide (Serva, Heidelberg, Germany) in PBS) and in-
termittent vortexing (30s). Pellets were resuspended for antibody
surface staining (30 min, dark, on ice), followed by fixation,
permeabilization (BD Lysing Solution and Permeabilizing solution
2; used according to the manufacturer’s instructions), and
intracellular staining (see surface staining).
Monoclonal antibodies
Pacific-blue (PB)-labeled anti-CD3, AmCyan-labeled anti-CD4,
Fluorescein-Iso-Thio-Cyanate (FITC)-labeled anti-IL2, anti-
CD27, and anti-CD28, Phycoerythrin(PE)-labeled anti-IL-2 and
anti-CD62L, Peridine-Chlorophyll(PerCP)-labeled anti-CD3, Al-
lophyocyanine(APC)-labeled anti-IFN-c were purchased from BD.
PE-Texas-Red-(ECD)-labeled anti-CD4 and Phycoerythrin(PE)-
labeled anti-CD57 where purchased from Beckman-Coulter
T-Cell Marker for Active TB
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from Caltag (Hamburg, Germany). Fluorochrome-labeled isotype
controls were used as appropriate.
Flow-cytometric analysis
Flow-cytometry was performed on an LSR II flow-cytometer (BD).
At least 250,000 lymphocytes were acquired per tube. Data files
were analyzed using FACSDiva
TM software (BD). The percentage
of IFN-c-positive CD4 T-cells was determined by a standardized
strategy. The median number of positive events evaluated was
479. Given 479 events the 95%-confidence interval for a pro-
portion of CD27-negative events determined to be 50% would be
50+/2 4.5% (given normal distribution). Distributions based on
a minimum of 50 and 20 events were considered for tuberculin
and ESAT-6 stimulated samples, respectively, the latter only when
comparing the distribution of tuberculin and ESAT-6 specific
CD4 T-cells. Whether more than 50 tuberculin-reactive CD4 T-
cells could be collected depended on the patient lymphocyte count,
reactivity, and the number of stimuli and antibody panels tested.
Peptides and antigens
The ESAT-6 peptide set was made in-house (21 peptides, 15
amino-acid length, 11 overlaps between peptides, covering the
Swiss-Prot Q57165 sequence). Peptides were dissolved in DMSO
and used as described above. Tuberculin (PPD) was purchased
from SSI (Copenhagen, Denmark).
Cytokine measurements
Supernatants of overnight stimulated samples (same conditions as
above save addition of Brefeldin A) were stored at 280uC until
measurement using a custom ordered bead-array (Lincoplex
TM)
by Linco Research (Stockholm, Sweden) and a Luminex-xMAP
System.
Personnel involved in grouping patients, preparing,
reading, and analysing samples
The reference laboratory tests (smear and culture) were performed
by fully trained hospital and laboratory personnel (routine TB
diagnostic lab). Biopsies were analysed by a fully trained
experienced pathologist. X-rays were evaluated by fully trained
and experienced chest physicians/radiologists. All samples were
prepared and measured by 2 laboratory scientists with long-term
experience in flow-cytometry. Flow-cytometric data analysis was
performed by a highly experienced medical scientist.
Statistical analysis
SPSS 11.0 (SPSS Inc, Chicago, USA) software was used.
Differences between paired samples were analysed using the
Wilcoxon test. Receiver Operating Characteristic (ROC)-analysis
was used to define cut-off values. Differences between unpaired
sample were tested using the Mann-Whitney U-test.
RESULTS
Initial observation: marked down-regulation of
CD27 on tuberculin-specific T-cells in active
pulmonary TB
The expression of ‘‘classic’’ markers of T-cell differentiation
[12,14] on tuberculin-reactive CD4 T-cells in a representative
patient with smear and/or culture positive TB is shown in Figure 2.
Expression of CD27 was high, intermediate, or absent (black
highlighted events in panel B), expression of the chemokine
receptor, CCR7, and the adhesion molecule, L-Selectin (CD62L),
was generally absent, and expression of the costimulatory receptor,
CD28, was generally high (panels C and D). Expression of both
the traditional memory markers, CD45RA and RO, was in-
termediate (not shown). As previously reported [11], the majority
Figure 1. Flow diagram of the blind prospective diagnostic study. Eligible patients were recruited by the admitting physician. Diagnostic standard
refers to the standard diagnostic procedure for TB in this hospital including history, X-ray, sputum microscopy and culture, PCR, biopsy and histology
where applicable. TST=tuberculin skin test
doi:10.1371/journal.pone.0000735.g001
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TNF-a and IL-2 (not shown). The phenotype of tuberculin-
reactive T-helper cells was similar in the control group (BCG
vaccines) with one exception: the percentage of CD27-negative
tuberculin-reactive CD4 T-cells was clearly higher in the patients.
In particular, there was a significant difference between patients
with smear and/or culture positive pulmonary TB and unexposed
controls (Fig.3). Five individuals classified as having latent TB
infection had values in between the patients and the unexposed/
highly exposed controls (Fig. 3).
To be statistically viable, results shown in Figure 3 only include
percentages based on more than 50 IFN-c producing cells (median: 479
cells). Receiver-Operating-Characteristics (ROC)-analysis identi-
fied a threshold of 49% (percentage of CD27-negative/IFN-c-
positive tuberculin-reactive CD4 T-cells) that best discriminated
patients and controls (sensitivity=100%, specificity=85.7%,
positive predictive value=100%, negative predictive val-
ue=94%). Notably, there was no correlation between the
reactivity to tuberculin (in % reactive cells or IFN-c levels in the
supernatant) and the proportion of CD27-negative T-cells (not
shown). This initial observation suggested that the percentage of
CD27-expressing TB specific T-cells decreases as a function of
increasing TB exposure, with a percentage that is high in
unexposed individuals, intermediate in latent TB infection, and
low in smear and/or culture positive TB.
Blinded evaluation confirms the utility of measuring
CD27 on tuberculin reactive T-cells
To further explore the possibility of diagnosing TB based on the
CD27-expression of TB specific T-helper-cells, a prospective blinded
study was designed. To exclude an influence of the clinical diagnosis
on sample analysis (e.g. the boundary dividing CD27-pos. and –neg.
cells), samples received in the lab were number-coded. Clinical
information was not given to the lab investigators until results had
been transmitted to the clinicians in print. For this study, patients
with pulmonary TB were included no later than 2 months after
beginning of tuberculosis therapy (n=22, fresh TB) or at the time of
follow-up 444 +/2 94 days (mean +/2 STD) after beginning of
treatment (n=9, follow-up). They were divided into, first, smear
and/or culture positive pulmonary TB (n=12, group I), second,
smear and culture negative pulmonary TB (n=10, group II), and
third, pulmonary TB treated at follow up who had been treated for
one year (n=9, group III). Patients with other pulmonary or
cardiovascular complaints were used as controls (n =20, group IV).
A tuberculin skin test (TST) was performed on a majority of the
control patients and those with a positive result .5m m w e r e
excluded (n=3). Please see Table 1 for details on all groups.
The blind study confirmed the findings of the initial study
(Figure 4 A). Patients with smear and/or culture positive TB could
be readily discriminated from control patients, but also, from
Figure 2. Distribution of tuberculin-reactive CD4 T-cells among the subsets defined by classic memory/naı ¨ve markers. PBMC were stained with
the indicated monoclonal antibodies. Panel A shows CD3 T-cells, panels B-D only CD4 T-cells. IFN-c-producing ex-vivo tuberculin-reactive events are
highlighted black. The dotted horizontal line in B shows the limit set for CD27-positivity. Representative results from one patient with active TB are
shown.
doi:10.1371/journal.pone.0000735.g002
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a threshold of 48% (determined by ROC-analysis) above which
cases would be diagnosed to have smear and/or culture positive
TB, both sensitivity and specificity would be 100% (p=0.000 in
both cases, Chi-square test); also, positive and negative predictive
values would be 100%. Using the original threshold of 49%
suggested by the initial study, there would have been one false
negative per group comparison. No distinction was possible
between groups 2, 3, and 4. Table 2 shows a cross tabulation of
results by patient group.
Figure 4 B shows the correlation between the percentages of
CD27-negative IFN-c producing CD4 T-cells in response to
tuberculin and ESAT-6 stimulation, suggesting very similar
expression levels and distribution of CD27 on the responding T-
cells. There was no significant correlation between the magnitudes
(frequencies) of tuberculin and ESAT-6 specific CD4 T-cell
responses between any of the groups.
As in the initial study, reactivity to tuberculin measured either by
IFN-c in the supernatant or the frequency of tuberculin-reactive
CD4 T-cells would not have been able to discriminate the groups
(see Table 1). ESAT-6 reactivity, both using ICS and IFN-c
measurement in the supernatant was not found in all TB patients
although the diagnosis of TB was fully confirmed by clinical
presentation, X-ray, smear, and/or biopsy. Also, unexpectedly,
ESAT-6 reactivity occurred in a few of the control patients,
suggesting they might have been latently infected. As with tuberculin
induced responses, the mere presence/absence or size of T-cell
responses to ESAT-6 alone would not have been helpful for the
diagnosisofactivepulmonaryTBinthiscohort(seeTable1).Table3
shows responder frequencies in the different TB related tests used in
this study, for the purpose of this comparison only, IFN-c levels
exceeding 0.1 IU/ml were arbitrarily considered a ‘positive’ result.
Changes in treated patients occur very slowly
In group III, 3 of 4 patients with-initially-smear positive TB had
percentages of CD27-neg. tuberculin-responsive CD4 T-cells
above 50%, still one year after therapy, indicating that CD27
expression was not restored quickly after treatment (see Fig. 4A).
However, the interval between the collection date of the analyzed
blood sample and that of the last positive sputum sample (culture
and/or microscopy) in each patient correlated albeit weakly with
the percentage of CD27-negative tuberculin-reactive CD4 T-cells
(0.562, p=0.029) (Figure 5 A). The collection time of the last
positive sputum sample is the closest surrogate for the last time
point when TB was not contained with subsequent cultures
turning out negative. If free access of mycobacteria to the
bronchial mucosa was involved in driving the continued
differentiation of tuberculin specific CD4 T-cells, this time point
would be considered a turning point from which onwards
differentiation may stop or revert. To further explore this
Figure 3. Significantly fewer tuberculin-reactive CD4 T-cells express CD27 in TB-patients than in controls. Proportions of CD27-positive and
negative cells were based on a minimum of 50 IFN-c positive events. Vertical numbers indicate evaluated events (median and range). Controls
included unexposed controls, professionally TB-exposed health care workers, and donors with latent infection. A threshold of 49% would effectively
discriminate between patients and controls (dotted line). Controls with latent TB infection had higher values than individuals with no known
exposure to TB.
doi:10.1371/journal.pone.0000735.g003
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..................................................................................................................................................
Dx
a code Age (years) sex TST (mm) Tuberculin stimulated (10 mg per ml) ESAT-6 stimulated (20 mg of peptide per ml)
CD4 T-cells (%)
b IFN-c (IU)
c CD4 T-cells (%)
b FN-c(IU)
c
Patients with smear and/or culture positive pulmonary TB
1 B1 45.94 m 6 0.1430 4.90 0.0158 0.15
1 B3 81.57 f 10 0.2962 1.33 0.0000 nd
1 B11 32.96 m nd 0.1833 3.77 0.0066 0.00
1 B12 50.63 f 10 0.1298 4.00 0.0029 0.00
1 B33 31.85 f nd 0.0143 0.69 0.0010 0.00
1 B48 66.23 m nd 0.0740 1.42 0.0005 0.00
1 B49 14.99 m ,5 0.1031 10.59 0.0007 0.00
1 B52 71.11 m ,5 0.1374 1.10 0.0143 0.21
1 B61 28.51 m nd 0.1411 9.03 0.0494 1.46
1 B75 75.85 f 35 0.3035 10.23 Nd 1.00
1 B76 95.69 m nd 1.2005 4.08 0.0121 0.01
1 B77 28.64 f 5 0.8713 44.79 0.0439 1.83
Patients with smear and culture negative pulmonary TB
3 B21 35.33 f 20 0.1405 1.99 0.0023 0.00
2 B29 69.58 m ,5 0.0012 0.00 0.0013 0.00
2 B40 50.41 m 10 0.3424 12.89 0.0003 0.00
2 B42 41.97 m 28 0.1359 5.86 0.0005 0.00
4 B46 71.33 m 30 0.5766 13.37 0.0360 0.69
2 B47 66.7 m ,5 0.0200 0.04 0.0043 0.00
2 B59 64.73 m 5 0.0926 0.43 0.0012 0.00
2 B65 74.38 m nd 0.0034 0.00 0.0049 0.00
2 B70 70.99 f ,5 0.0026 0.03 0.0016 0.00
2 B73 15.82 m 10 0.0145 0.00 0.0046 0.00
Patients with pulmonary TB at least one year after beginning of treatment
2 B7 21.22 m 12 0.1996 6.59 0.0209 0.41
1 B22 50.24 f nd 0.3246 16.66 0.0023 0.12
1 B27 58.56 m 16 0.2539 7.79 0.0018 0.00
1 B43 76.38 f 12 0.7997 3.23 0.0049 0.01
1 B51 36.46 m nd 0.0221 nd 0.0222 nd
1 B56 61.23 f ,5 0.0417 0.24 0.0178 0.15
1 B57 60.11 m ,5 0.0788 2.18 0.0006 0.00
1 B58 37.47 f 25 0.0308 2.41 0.0252 0.26
1 B60 49.69 m 5 0.0764 2.59 0.0009 0.00
Control patients
6 B8 44.68 f ,5 0.0151 0.00 0.0039 0.00
6 B10 58.92 m ,5 0.0471 0.00 0.0161 0.00
6 B15 71.3 m ,5 0.0252 0.01 0.0001 nd
6 B16 55.11 f nd 0.0022 0.02 nd 0.00
6 B17 40.84 m ,5 0.1161 1.00 0.0030 0.00
6 B18 65.85 f nd 0.0613 0.25 0.0121 nd
6 B23 70.01 m ,5 0.2552 2.55 0.0060 0.00
6 B24 42.35 m ,5 0.0273 0.02 0.0046 0.00
6 B25 76.07 f ,5 0.0255 0.00 0.0012 0.00
6 B26 69.91 f nd 0.0086 0.00 0.0000 7.12
6 B28 64.3 m ,5 0.0078 0.23 0.0007 0.00
6 B35 48.05 m ,5 0.0058 0.27 0.0013 0.00
6 B36 58.67 m nd 0.0088 0.16 0.0063 0.00
6 B39 47.24 m ,5 0.3653 6.06 0.0040 0.72
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PLoS ONE | www.plosone.org 6 August 2007 | Issue 8 | e735hypothesis using longitudinal rather than cross-sectional data,
additional follow-up samples from patients with smear and/or
culture positive pulmonary TB were requested, and assessed, as
before, in a blinded manner. Seven samples from time points
between nine weeks and one year after the first sample were
obtained. However, we found that CD27-expression on the
tuberculin-reactive CD4 T-cells was fairly stable over the
measured treatment intervals up to one year (Figure 5 B) which
did not confirm the idea of reversion of this parameter, at least not
within the time frame of one year.
DISCUSSION
Our results have demonstrated that CD27-expression on ex-vivo
short term stimulated tuberculin specific CD4 T-cells is a highly
discriminating biomarker for active pulmonary TB. It will also
have utility for tracing TB contacts with latent TB infection. In this
cohort of patients and controls the phenotype of tuberculin-
reactive T-cells was more informative than quantitative measures
of reactivity or target protein specificity.
While paradigms for compartmentalizing antigen dependent T-
cell differentiation based on surface markers and functionality
have been an area of major interest for a number of years
[14,20,21], patterns of T-cell differentiation have not previously
been used to help making a clinical diagnosis. In TB, such an
approach appears very attractive, in particular in a BCG
vaccinated population, where an immune response to tuberculin
is not diagnostic of infection. Our approach utilizes the fact that
BCG vaccination is a single stimulus and will drive T-cell
differentiation only to a limited extent. Only once additional
exposure to TB occurs will additional differentiation occur. It is
exactly that increment of differentiation which leads us to the
diagnosis, exploiting the fact that boosting of BCG-induced
responses exclusively occurs by subsequent exposure to TB.
The degree of T-cell differentiation will likely depend on the
circumstances, length, and frequency of exposure, and also the
efficiency of the T-cell response in containing infection. These are
obviously interdependent factors. In the 6 BCG vaccinated
unexposed controls shown in Fig. 3, the percentage of CD27-
negative tuberculin-reactive CD4 T-cells did not exceed 35%.
This may be the degree of differentiation expected in response to
BCG vaccination alone. Fig. 3 suggests that there is more
differentiation in individuals with continued exposure. Highly
exposed individuals show levels of CD27-neg. tuberculin-reactive
CD4 T-cells similar to those found in latent TB infection and even
acute smear and/or culture positive TB. It is not known whether
contact with TB is required in order to maintain a minimum of
tuberculin-reactive CD4 T-cells throughout life, however, our data
suggests there are gradual differences in exposure related
differentiation, rather than everything or nothing. It may well be
that a minimum of exposure helps to maintain a minimum
response, whereas a higher degree or frequency of exposure (such
as in hospital personnel) will push differentiation.
The fact that we did not observe more CD27-neg. tuberculin-
reactive CD4 T-cells in patients with smear and culture negative
TB than in control patients is of interest, since there was a clear
distinction between unexposed donors and individuals with latent
TB (Fig. 3). Smear negative TB would be expected to have
developed from TB that was once latent or active, so that reversion
of the predominantly CD27-neg. phenotype must have occurred
with time. Before active smear and culture negative TB was
diagnosed (usually initiated by doing a chest X-ray for other reasons)
the infection may have been contained and inactive for years. All
patients in this group had typical findings on chest films, and 8 out of
10 had positive biopsy results. In two patients the diagnosis was
partly based on a therapy response (reduction of lesions), in the
remaining patients disease activity was not demonstrated.
Recently it was shown in a TB mouse model that CD27-neg.
lymphocytes isolated from lung produced more IFN-c following
stimulation with tuberculin than their CD27-pos. counterparts,
which agrees with our findings in humans [19]. In smear and/or
culture positive TB more than half of the tuberculin-reactive IFN-
c producing CD4 T-cells had lost CD27. Direct exposure of
bronchus associated lymphatic tissue (BALT) to free mycobacteria
may play an important role in triggering and sustaining T-cell
differentiation [22]. This might be mediated by alveolar macro-
phages that are activated via Toll Like Receptors or related
signalling pathways [23–25]. This would be considered an
‘‘uncontrolled’’ traffic of pathogens, causing responses that are
different in quality from those occurring as pathogens are
transported in and out of organized lesions which are under the
control of the immune system. We tentatively conclude that the
percentage of CD27-expressing tuberculin-reactive CD4 T-cells is
most likely a reflection of the degree of exposure of the bronchus
associated lymphatic system to free mycobacterial antigens.
Dx
a code Age (years) sex TST (mm) Tuberculin stimulated (10 mg per ml) ESAT-6 stimulated (20 mg of peptide per ml)
CD4 T-cells (%)
b IFN-c (IU)
c CD4 T-cells (%)
b FN-c(IU)
c
6 B41 43.94 m ,5 0.0019 0.18 0.0005 0.00
6 B44 73.7 m nd 0.1972 0.50 0.0243 0.13
6 B55 54.19 m ,5 0.0035 0.01 0.0017 0.00
amainstay of diagnosis: 1=positive culture and/or microscopy, 2=mycobacteria in biopsy, 3=therapy response, 4=typical chest film, TST .15 mm, positive response
to ESAT-6
bresults exceeding 1 positive event per 10,000 cells were counted as positive and are shown in bold
csome of these results exceed the threshold for positivity published for a commercial assay (Quantiferon Gold, Cellestis) of 0.35 IU.
doi:10.1371/journal.pone.0000735.t001
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Table 2. Crosstabulation of results in blind study.
......................................................................
Group CD27-neg. tuberculin reactive CD4 T-cells Total
, 48% .48%
10 1 1 1 1
26 0 6
33 3 6
48 0 8
Total 17 14 31
doi:10.1371/journal.pone.0000735.t002
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a in different TB related tests in the blind study.
..................................................................................................................................................
Patient group TST$5 mm tuberculin in vitro
b ICS vs. supernatant ESAT-6 in vitro
c ICS vs. supernatant
smear and/or culture positive TB (n=12) 5/7 12/12 vs. 12/12 5/11 vs. 5/11
smear and culture negative TB (n=10) 6/9 7/10 vs. 5/10 1/10 vs. 1/10
$1 year after beginning of TB treatment (n=8) 5/7 9/9 vs. 8/8 4/9 vs. 4/8
Control patients (n=17) 0/12 10/17 vs. 9/17 3/16 vs. 3/15
anot all test were performed in all individuals, numbers refer to positive test results per tested individuals
bfrequency of tuberculin-reactive CD4 T-cells (IFN-gamma) above 1/10,000 or IFN-gamma above 0.1 IU/ml (arbitrary value)
cfrequency of ESAT-6 reactive CD4 T-cells (IFN-gamma) above 1/10,000 or IFN-gamma above 0.1 IU/ml (arbitrary value)
doi:10.1371/journal.pone.0000735.t003
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Figure 4. Loss of CD27 on tuberculin-reactive CD4 T-cells identifies smear and/or culture positive TB. A: Patients with smear and/or culture
positive pulmonary TB were distinguishable from those with smear and culture negative pulmonary TB using a threshold of 48% (dotted line).
Patients more than 1 year after beginning of treatment mostly had values .48% if TB was initially smear positive (empty squares), and ,48%, if TB
was smear negative (filled squares). Statistically significant differences are indicated (Chi-square test). Primary end-point was the percentage of CD27-
negative cells among reactive cells. Vertical numbers indicate the number of evaluated events (median and range). B: Loss of CD27 expression on
tuberculin and ESAT-6 specific CD4 T-cells is closely correlated.
doi:10.1371/journal.pone.0000735.g004
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PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e735The combination of low CCR7 but high CD28 expression that
we observed on all tuberculin-reactive CD4 T-cells was recently
associated with lung homing, which is indeed a prominent feature
of tuberculin responsive CD4 T-cells [26].
The finding that ESAT-6 reactivity was not a good marker for
the diagnosis of active TB is in agreement with previous reports on
acute TB patients and controls for example in Brazil and The
Gambia [7,27], indicating that ESAT-6 responses are higher in
latent TB but not active TB than in controls. Of note, ESAT-6
reactivity is normally measured in epidemiological studies to detect
latent TB infection and not used to diagnose acute TB [1,4].
In order to rule out any bias related to subjective interpretation
of flow-cytometry data the second part of the study was performed
in a blinded fashion. This has fully confirmed our initial findings
and demonstrated that gating of CD27-negative T-cells is a robust
procedure. The fact that in some patients less than 50 IFN-c
producingcellswereavailableforassessingthepercentagesofCD27-
pos. and CD27-neg. cells reflects that our samples were stretched
somewhat to accommodate several stimuli and antibody panels per
sample in this pilot study. If only tuberculin had been used as
a stimulus in combination with just one antibody panel, we would
have had largely sufficient numbers of events in all TB patients.
In conclusion, our results argue that the phenotype of TB
specific T-cells measured at the single cell level has considerable
diagnostic potential and is more relevant than response quantity. A
similar change of paradigm has already taken place in the HIV
field [28,29].
Since results can be obtained in less than 24 hours, this method
could have utility in situations where diagnostic decisions are
a matter of urgency. Smear and/or culture positive TB is a hazard
to society and unnecessary hospitalizations are costly. It is,
therefore, important to identify these patients rapidly. In this
respect, our new assay is a considerable advance and calls for more
research into using T-cell differentiation in diagnostic procedures
in TB and other fields.
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